Term
| Psychomotor: All cause excitement, euphoria, decreased fatigue, increased motor activity |
|
Definition
|
|
Term
| Few clinical uses but important drugs of abuse |
|
Definition
|
|
Term
MOA: Phophiesterase inhibitors (increase cAMP, cGMP)
Adenosine receptor antagonists |
|
Definition
|
|
Term
| CNS: decrease fatigue, increase mental alertness |
|
Definition
|
|
Term
CV : + chronotropic and ionotropic effects
related to cAMP level in the heart; palpations, and arrythmias at toxic levels |
|
Definition
|
|
Term
| Diuretics action (mild w/ caffeine) |
|
Definition
|
|
Term
| gastric mucosa: increase HCL acid production |
|
Definition
|
|
Term
Therapeutic uses : relaxes smooth muscle in bronchioles
(NOT ANYMORE, NO THERAPEUTIC USE) |
|
Definition
|
|
Term
Well absorbed orally
total body distribution
cross lacenta and excreted in breast milk
metabolized & excreted in liver |
|
Definition
| methlyxanthine pharmacokinetics |
|
|
Term
| Insomnia, anxiety, agitation |
|
Definition
| adverse effects of methyxanthines |
|
|
Term
| Toxicity, emesis, tremor, convulsions |
|
Definition
| adverse effects of methylxanthines in high doses |
|
|
Term
|
Definition
|
|
Term
| Second to caffeine as most widely used CNS stimulant |
|
Definition
|
|
Term
| one of the most addicting substances known |
|
Definition
|
|
Term
MOA : CNS and ganglionic stimulation
(high doses causes blockade) |
|
Definition
|
|
Term
| Euphoia, arousal, relaxation, increase attention |
|
Definition
|
|
Term
central respiratory paralysis and severe HYPOtension
(essentially shutting down the ANS) |
|
Definition
|
|
Term
increase BP and HR
Decrease coronary blood flow, also observed w/ second hand smoke (ETS)
increase motor activity of bowel |
|
Definition
| peripheral actions of nicotine |
|
|
Term
| Highly lipid soluble, absorbed thru oral mucosa, GI tract and skin |
|
Definition
| nicotine pharmacokinetics |
|
|
Term
irritability and tremors
intestinal cramping and diarrhea
increased HR and BP
increased metabolism of many drugs |
|
Definition
| adverse effects of nicotine |
|
|
Term
| Physical dependence (possibly psychological dependence), anxiety, agitation, HA, insomnia |
|
Definition
|
|
Term
|
Definition
nicotine patch
buproprion SR (Zyban)
(Chantix) |
|
|
Term
Antidepressant, DA/NE reuptake inhibitor
smoking cessation |
|
Definition
|
|
Term
most effective drug available, nicotinic receptor partial agonist
smoking cessation |
|
Definition
|
|
Term
more potent, less effacious than nicotine
results in DA release (reward) |
|
Definition
|
|
Term
| most common adverse effects: nausea, sleep disturbances, ABNL dreams, HA, constipation, vomiting, flatulence, and xerostomia |
|
Definition
|
|
Term
| MOA: blockage of NE, 5HT, and DA reuptake, prolongs the dopaminergic effects in thebrain |
|
Definition
|
|
Term
Acutely increase mental awareness and euphoria
can cause hallucinations, delusions, and paranoid |
|
Definition
|
|
Term
| High doses: tremors, convulsions, respiratory, MI, and vasomotor depression |
|
Definition
|
|
Term
| Therapeutic uses: local anesthetic, only local anesthetic that has intrinsic vasoconstricting activity |
|
Definition
|
|
Term
| AE: anxiety rxn (HTN, tachycardia, sweating, and paranoid), depression, cardiac arrhythmias, seizures, incidence of MI unrelated to dose, duration, or route |
|
Definition
|
|
Term
| effects similar to cocaine |
|
Definition
|
|
Term
| MOA: releases intracellular stores of catecholamines and blocks MAO |
|
Definition
|
|
Term
Actions CNS: stimulates cerebrospinal axis, cortex, brain stem, and medulla
(increases alertness, decrease fatigue, appetite, & insomnia) |
|
Definition
|
|
Term
|
Definition
|
|
Term
| SAS: stimulated indirectly |
|
Definition
|
|
Term
| Therapeutic uses : ADD, narcolepsy |
|
Definition
|
|
Term
| complete GI absorption, liver metabolism and urine excretion; euphoria lasts 4-6 hours |
|
Definition
|
|
Term
| Methylphenidate is used for |
|
Definition
|
|
Term
|
Definition
Lysergic Acid Diethylamide (LSD)
tetrahydrocannabinol
phencyclidine (PCP) |
|
|
